Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease
Abstract Sarcopenia occurs in patients with Crohn's disease (CD). However, the association between sarcopenia and loss of response (LOR) to biologic agents remains unclear. This study explored such an association in CD patients. This retrospective study included 94 CD patients who received biol...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-11-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.13621 |
_version_ | 1797627415032233984 |
---|---|
author | Jingjing Liu Hongye Tang Tingting Lin Jiangchuan Wang Wenjing Cui Chao Xie Zhongqiu Wang Yugen Chen Xiao Chen |
author_facet | Jingjing Liu Hongye Tang Tingting Lin Jiangchuan Wang Wenjing Cui Chao Xie Zhongqiu Wang Yugen Chen Xiao Chen |
author_sort | Jingjing Liu |
collection | DOAJ |
description | Abstract Sarcopenia occurs in patients with Crohn's disease (CD). However, the association between sarcopenia and loss of response (LOR) to biologic agents remains unclear. This study explored such an association in CD patients. This retrospective study included 94 CD patients who received biologic therapy. The skeletal muscle cross‐sectional area at the third lumbar was assessed by computed tomography or magnetic resonance imaging for sarcopenia evaluation. A LOR was defined by fecal calprotectin (FC) < 250 μg/g or >50% reduction from baseline levels or other factors, such as the used agent being replaced by other biologic agents. The association between sarcopenia and LOR was assessed by logistic regression analysis. LOR was observed in 54 patients (57.4%). The prevalence of sarcopenia in the LOR group was higher than that in response group (70.4% vs. 40.0%, p = 0.003). Sarcopenia (odds ratio [OR] = 3.89, 95% confidence interval [CI]: 1.31–11.54), Montreal L1 type (OR = 0.20, 95% CI: 0.06–0.60), perianal lesions (OR = 4.08, 95% CI: 1.31–12.70), and monocytes percentage (OR = 1.27, 95% CI: 1.02–1.57) at baseline were independent associated factors for LOR. Sarcopenia was also associated with LOR in patients who received infliximab (OR = 3.31, 95% CI: 1.11–9.87). Montreal L1 type, perianal lesions, and monocytes percentage (Model 1), and with additional consideration of sarcopenia (Model 2), were developed to predict LOR. Model 2 showed better performance than Model 1 (area under the curve [AUC] 0.82 vs. 0.75). Sarcopenia was associated with the LOR to biological agents or infliximab in adult patients with CD. |
first_indexed | 2024-03-11T10:23:48Z |
format | Article |
id | doaj.art-9337696de07f4cd49357dcf0345b1938 |
institution | Directory Open Access Journal |
issn | 1752-8054 1752-8062 |
language | English |
last_indexed | 2024-03-11T10:23:48Z |
publishDate | 2023-11-01 |
publisher | Wiley |
record_format | Article |
series | Clinical and Translational Science |
spelling | doaj.art-9337696de07f4cd49357dcf0345b19382023-11-16T04:14:35ZengWileyClinical and Translational Science1752-80541752-80622023-11-0116112209222110.1111/cts.13621Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's diseaseJingjing Liu0Hongye Tang1Tingting Lin2Jiangchuan Wang3Wenjing Cui4Chao Xie5Zhongqiu Wang6Yugen Chen7Xiao Chen8Department of Radiology Funan County People's Hospital Fuyang Anhui ChinaDepartment of Radiology The Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing ChinaDepartment of Radiology The Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing ChinaDepartment of Radiology The Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing ChinaDepartment of Radiology The Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing ChinaCenter of Musculoskeletal Research University of Rochester School of Medicine Rochester New York USADepartment of Radiology The Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing ChinaDepartment of Colon and Rectum Surgery The Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing ChinaDepartment of Radiology The Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing ChinaAbstract Sarcopenia occurs in patients with Crohn's disease (CD). However, the association between sarcopenia and loss of response (LOR) to biologic agents remains unclear. This study explored such an association in CD patients. This retrospective study included 94 CD patients who received biologic therapy. The skeletal muscle cross‐sectional area at the third lumbar was assessed by computed tomography or magnetic resonance imaging for sarcopenia evaluation. A LOR was defined by fecal calprotectin (FC) < 250 μg/g or >50% reduction from baseline levels or other factors, such as the used agent being replaced by other biologic agents. The association between sarcopenia and LOR was assessed by logistic regression analysis. LOR was observed in 54 patients (57.4%). The prevalence of sarcopenia in the LOR group was higher than that in response group (70.4% vs. 40.0%, p = 0.003). Sarcopenia (odds ratio [OR] = 3.89, 95% confidence interval [CI]: 1.31–11.54), Montreal L1 type (OR = 0.20, 95% CI: 0.06–0.60), perianal lesions (OR = 4.08, 95% CI: 1.31–12.70), and monocytes percentage (OR = 1.27, 95% CI: 1.02–1.57) at baseline were independent associated factors for LOR. Sarcopenia was also associated with LOR in patients who received infliximab (OR = 3.31, 95% CI: 1.11–9.87). Montreal L1 type, perianal lesions, and monocytes percentage (Model 1), and with additional consideration of sarcopenia (Model 2), were developed to predict LOR. Model 2 showed better performance than Model 1 (area under the curve [AUC] 0.82 vs. 0.75). Sarcopenia was associated with the LOR to biological agents or infliximab in adult patients with CD.https://doi.org/10.1111/cts.13621 |
spellingShingle | Jingjing Liu Hongye Tang Tingting Lin Jiangchuan Wang Wenjing Cui Chao Xie Zhongqiu Wang Yugen Chen Xiao Chen Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease Clinical and Translational Science |
title | Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease |
title_full | Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease |
title_fullStr | Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease |
title_full_unstemmed | Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease |
title_short | Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease |
title_sort | sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with crohn s disease |
url | https://doi.org/10.1111/cts.13621 |
work_keys_str_mv | AT jingjingliu sarcopeniaassessedbycomputedtomographyormagneticresonanceimagingisassociatedwiththelossofresponsetobiologictherapiesinadultpatientswithcrohnsdisease AT hongyetang sarcopeniaassessedbycomputedtomographyormagneticresonanceimagingisassociatedwiththelossofresponsetobiologictherapiesinadultpatientswithcrohnsdisease AT tingtinglin sarcopeniaassessedbycomputedtomographyormagneticresonanceimagingisassociatedwiththelossofresponsetobiologictherapiesinadultpatientswithcrohnsdisease AT jiangchuanwang sarcopeniaassessedbycomputedtomographyormagneticresonanceimagingisassociatedwiththelossofresponsetobiologictherapiesinadultpatientswithcrohnsdisease AT wenjingcui sarcopeniaassessedbycomputedtomographyormagneticresonanceimagingisassociatedwiththelossofresponsetobiologictherapiesinadultpatientswithcrohnsdisease AT chaoxie sarcopeniaassessedbycomputedtomographyormagneticresonanceimagingisassociatedwiththelossofresponsetobiologictherapiesinadultpatientswithcrohnsdisease AT zhongqiuwang sarcopeniaassessedbycomputedtomographyormagneticresonanceimagingisassociatedwiththelossofresponsetobiologictherapiesinadultpatientswithcrohnsdisease AT yugenchen sarcopeniaassessedbycomputedtomographyormagneticresonanceimagingisassociatedwiththelossofresponsetobiologictherapiesinadultpatientswithcrohnsdisease AT xiaochen sarcopeniaassessedbycomputedtomographyormagneticresonanceimagingisassociatedwiththelossofresponsetobiologictherapiesinadultpatientswithcrohnsdisease |